MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1253/circj.cj-20-0636

Медицинская библиотека · Circulation journal : official journal of the Japanese Circulation Society · 2020

A Multicenter Prospective Observational Cohort Study to Investigate the Effectiveness and Safety of Rivaroxaban in Japanese Venous Thromboembolism Patients (The J'xactly Study).

Okumura Yasuo, Fukuda Ikuo, Nakamura Mashio, Yamada Norikazu, Takayama Morimasa, Maeda Hideaki, Yamashita Takeshi, Ikeda Takanori, Mo Makoto, Kobayashi Takao, Niwa Akihiro, Matsuo Hiroshi, Yokoi Hiroyoshi, Koga Masatoshi, Yamazaki Tsutomu, Hirayama Atsushi, J’xactly Investigators

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

There is insufficient real-world data on the current status of Japanese patients with venous thromboembolism (VTE) or its treatment and prevention with rivaroxaban.

METHODS AND

RESULTS

In this multicenter, prospective, observational study conducted in Japan, 1,039 patients with acute symptomatic/asymptomatic deep vein thrombosis (DVT) and pulmonary embolism (PE) with or without DVT prescribed rivaroxaban were enrolled at 152 institutions and observed for a median of 21.3 months. Mean age was 68.0±14.7 years, mean body weight was 60.3±14.1 kg, 59.0% were females, and 19.0% had active cancer. Incidences of recurrence or aggravation of symptomatic VTE (primary effectiveness outcome) and major bleeding (principal safety outcome) were 2.6% and 2.9% per patient-year, respectively. These outcomes did not differ between patients with DVT and those with PE (primary effectiveness outcome: 2.6% vs. 2.5% per patient-year, P=0.810; principal safety outcome: 3.5% vs. 2.4% per patient-year, P=0.394). The incidence of composite clinically relevant events, including recurrence or aggravation of symptomatic VTE, acute coronary syndrome, ischemic stroke, all-cause death, or major bleeding events, was 9.2% per patient-year. Multivariate analysis revealed that male sex, being underweight, having active cancer, chronic heart and lung disease, and previous stroke were independent determinants for composite clinically relevant events.

CONCLUSIONS

In Japanese clinical practice, a single-drug approach with rivaroxaban was demonstrated to be a valuable treatment for a broad range of VTE patients.

Для цитирования: Okumura Yasuo, Fukuda Ikuo, Nakamura Mashio, Yamada Norikazu, Takayama Morimasa, Maeda Hideaki, Yamashita Takeshi, Ikeda Takanori, Mo Makoto, Kobayashi Takao, Niwa Akihiro, Matsuo Hiroshi, Yokoi Hiroyoshi, Koga Masatoshi, Yamazaki Tsutomu, Hirayama Atsushi, J’xactly Investigators. A Multicenter Prospective Observational Cohort Study to Investigate the Effectiveness and Safety of Rivaroxaban in Japanese Venous Thromboembolism Patients (The J'xactly Study).. Circulation journal : official journal of the Japanese Circulation Society. 2020. DOI: 10.1253/circj.cj-20-0636.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.